Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis

    JAMA
    |October 26, 2002
    PubMed

    Insights

    Elevated total blood homocysteine is a modest predictor of ischemic heart disease (IHD) and stroke risk. Lowering homocysteine levels by 25% was associated with reduced IHD and stroke risk in a meta-analysis.

    Area of Science:

    • Cardiovascular Epidemiology
    • Clinical Biochemistry

    Background:

    • Elevated total blood homocysteine concentrations have been linked to increased risk of ischemic heart disease (IHD) and stroke.
    • Understanding the precise relationship between homocysteine and vascular disease is crucial for risk assessment.

    Purpose of the Study:

    • To systematically assess the association between homocysteine concentrations and the risk of vascular diseases, specifically IHD and stroke.

    Main Methods:

    • A comprehensive literature search of MEDLINE (1966-1999) identified observational studies on homocysteine and vascular disease risk.
    • Meta-analysis of individual participant data from 30 studies (5073 IHD events, 1113 stroke events) was performed.
    • Adjustments were made for cardiovascular risk factors and regression dilution bias.

    Main Results:

    • A 25% reduction in usual homocysteine levels (approx. 3 micromol/L) was associated with an 11% lower IHD risk (OR, 0.89) and a 19% lower stroke risk (OR, 0.81).
    • Associations were stronger in retrospective studies compared to prospective studies.

    Conclusions:

    • Elevated homocysteine appears to be a modest, independent predictor of IHD and stroke risk in healthy individuals.
    • Further research, including genetic studies and randomized trials of vitamin supplementation, is needed to confirm causality and therapeutic potential.
    Abstract

    Related Concept Videos

    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

    Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

    Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
    These markers indicate stress or strain on the heart muscle:
    Natriuretic Peptides (BNP)
    Cardiac myocytes produce these hormones in response to ventricular stretching...
    Coronary Artery Disease IV: Preventive Measures01:26

    Coronary Artery Disease IV: Preventive Measures

    Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
    Heart Failure I: Introduction01:27

    Heart Failure I: Introduction

    Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    Heart Failure III: Clinical Manifestations01:26

    Heart Failure III: Clinical Manifestations

    Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...